Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Chemotherapy
88%
Cytoreductive Surgery
87%
Hepatectomy
81%
Adenocarcinoma
78%
Learning Curve
73%
Adjuvant Therapy
73%
Pancreaticoduodenectomy
73%
Overall Survival
66%
Odds Ratio
65%
Morbidity
62%
Neoplasm
62%
Malignant Neoplasm
60%
Hyperthermic Intraperitoneal Chemotherapy
52%
Surgery
52%
Hazard Ratio
40%
Gastrectomy
34%
Adjuvant Chemotherapy
32%
Propensity Score Matching
32%
Pancreas Adenocarcinoma
31%
Pancreatectomy
31%
Neuroendocrine Tumor
31%
Randomized Controlled Trial
30%
Pancreas Cancer
30%
Peritoneum Metastasis
30%
Tumor
28%
Cancer
28%
Pancreas Islet Cell Tumor
28%
Abdominal Cancer
27%
Bile
27%
Carcinoma
24%
Post-Operative Pancreatic Fistula
24%
Neoadjuvant Therapy
24%
Venous Thromboembolism
24%
Cohort Analysis
24%
Squamous Cell Carcinoma
24%
Neurinoma
24%
Platelet
24%
Foregut
24%
Nucleic Acid
24%
Melanoma Skin Cancer
24%
Thromboprophylaxis
24%
Extrahepatic Bile Duct
24%
Rectum Cancer
24%
Glomus Tumor
24%
Cholecystectomy
24%
Liver Disease
24%
Rectum Resection
24%
Epidural Drug Administration
24%
Bilirubin
24%
Gastrointestinal Surgery
24%
Keyphrases
Cytoreductive Surgery
100%
Learning Curve
73%
Systemic Chemotherapy
65%
Hepatectomy
60%
Adenocarcinoma
56%
Open Pancreaticoduodenectomy
56%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
53%
National Surgical Quality Improvement Program (NSQIP)
48%
Robotic Pancreatoduodenectomy
48%
Adjuvant Therapy
44%
Postoperative Outcomes
37%
Odds Ratio
35%
Overall Survival
34%
Hazard Ratio
34%
Optimal Treatment
32%
Patient Selection
30%
Randomized Controlled Trial
30%
Surgical Treatment
30%
Peritoneal Metastasis
30%
Improved Outcomes
28%
Surgical Management
28%
Propensity Score Matching
27%
95% Confidence Interval
26%
30-day Mortality
24%
Patient Characteristics
24%
Risk Factors
24%
Robotics
24%
Bile Leak
24%
Postoperative Pancreatic Fistula
24%
Pancreatic Resection
24%
Oligometastatic
24%
Metastatic Gastric Cancer
24%
Minimally Invasive Approach
24%
Educational Outcomes
24%
T2N0
24%
Programmed Death-ligand 1 Expression
24%
Pure Primary Squamous Cell Carcinoma
24%
Adjuvant Chemotherapy
24%
Foregut
24%
Proctectomy
24%
Melanotic Schwannoma
24%
Thromboprophylaxis
24%
Pancreatic Cancer
24%
Neoadjuvant Therapy
24%
Decreased Risk
24%
Standard-of-care Chemotherapies
24%
Novelty Response
24%
Posthepatectomy Liver Failure
24%
Goblet
24%
Virtual Surgical
24%